MEDPACE HOLDINGS INC
MEDPNASDAQTrading Snapshot
- Day Range
- $618.04 – $626.18
- 52-Week Range
- $373.00 – $677.90
- Volume
- $3.08B
- Avg Volume
- $3.54B
- Shares Outstanding
- 27.9M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.53B
- Last Q Revenue
- $707M
- P/E Ratio
- 35.5
- P/S Ratio
- 6.2x
- EPS (TTM)
- $17.36
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −9.5%
Why Investors Own MEDP
- ✓High-growth profile — revenue up +34.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MEDPACE HOLDINGS INC
MEDP
StockOtter · stockotter.spaceAbout MEDPACE HOLDINGS INC
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Envestnet Asset Management Inc. Cuts Position in Medpace Holdings, Inc. $MEDP
Envestnet Asset Management Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 30.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissi
Medpace (NASDAQ:MEDP) CEO August Troendle Sells 21,883 Shares
Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 21,883 shares of the business's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $623.29, for
Medpace (NASDAQ:MEDP) CEO August Troendle Sells 49,018 Shares
Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 49,018 shares of Medpace stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a t
State Street Corp Buys 28,666 Shares of Medpace Holdings, Inc. $MEDP
State Street Corp increased its stake in Medpace Holdings, Inc. (NASDAQ: MEDP) by 4.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 710,895 shares of th
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Compa